Engraftment and outcomes of patients receiving myeloablative therapy followed by autologous peripheral blood stem cells with a low CD34+ cell content

Bone Marrow Transplantation
C H WeaverC D Buckner

Abstract

Engraftment kinetics after high-dose chemotherapy (HDC) were evaluated in patients receiving autologous peripheral blood stem cell (PBSC) infusions with a low CD34+ cell content. Forty-eight patients were infused with < 2.5 x 10(6) CD34+ cells/kg; 36 because of poor harvests and 12 because they electively received only a fraction of their harvested cells. A median of 2.12 x 10(6) CD34+ cells/kg (range, 1.17-2.48) were infused following one of seven different HDC regimens. All patients achieved absolute neutrophil counts > or = 0.5 x 10(9)/l at a median of day 11 (range, 9-16). Forty-seven patients achieved platelet counts > or = 20 x 10(9)/l at a median of day 14 (range, 8-250). Nine of 47 (19%) had platelet recovery after day 21, 4/47 (9%) after day 100 and one died on day 240 without platelet recovery. Twenty-six patients (54%) died of progressive disease in 51-762 days; 22 (46%) are alive at a median of 450 days (range, 94-1844), 17 (35%) of whom are surviving disease-free at a median of 494 days (range, 55-1263). No patient died as a direct consequence of low blood cell counts. These data demonstrate that PBSC products containing 1.17-2.48 x 10(6) CD34+ cells/kg resulted in relatively prompt neutrophil recovery in all patie...Continue Reading

Citations

Mar 2, 2005·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Ramakrishna L Reddy
Nov 30, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S LimatUNKNOWN Groupe Ouest Est d'étude des Leucémies et Autres Maladies du Sang (GOELAMS)
Mar 12, 2002·Therapeutic Apheresis : Official Journal of the International Society for Apheresis and the Japanese Society for Apheresis·Jan JansenLuke P Akard
Feb 15, 2001·Journal of Hematotherapy & Stem Cell Research·J G SharpS S Joshi
Aug 31, 2002·Journal of Hematotherapy & Stem Cell Research·Julián SevillaMiguel Angel Díaz
Mar 24, 2005·Journal of Cellular and Molecular Medicine·Jan JansenLuke P Akard
Feb 1, 2006·Expert Review of Anticancer Therapy·Eugene T H Ek, Peter F M Choong
Jul 5, 2008·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Cheng ZhangHong Liu
Jan 24, 2006·Pediatric Blood & Cancer·Stephan A GruppUNKNOWN Hematopoietic Stem Cell Transplant Discipline and the Neuroblastoma Disease Committee, Children's Oncology Group
Apr 3, 2007·Cytometry. Part B, Clinical Cytometry·Wilfried H B M LeveringJan W Gratama
Sep 30, 2006·Transfusion Medicine Reviews·Marloes R TijssenJaap Jan Zwaginga
Mar 27, 2007·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·David A HessJan A Nolta
Jul 25, 2003·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Jae-Lyun LeeCheolwon Suh
Jan 27, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Patrick StiffGary Calandra
Mar 6, 2007·Best Practice & Research. Clinical Haematology·Charles Linker
Aug 13, 2003·Cell Transplantation·Alison E WillingPaul R Sanberg
Mar 23, 2004·Bone Marrow Transplantation·T KuittinenE Jantunen
Jan 7, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C H WeaverC D Buckner
Oct 14, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kathelijne C J M KraalGodelieve A M Tytgat

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.